Browse the evidence

Semaglutide differs from other GLP-1 receptor agonists by having a longer half-life and producing greater weight loss.

Semaglutide may offer advantages over other GLP-1 agonists for weight loss due to its pharmacokinetic profile.

GLP-1 receptor agonists and co-agonists were associated with a lower risk of incident atrial fibrillation among individuals with overweight or obesity.

Practitioners may consider GLP-1RAs and co-agonists as potential options for reducing atrial fibrillation risk in overweight or obese patients.

All-cause mortality rate was 30% lower per SD greater METs (hazard ratio (HR) = 0.70; rate difference (RD), -2.71 deaths/1000 person-years).

Improving cardiorespiratory fitness can significantly lower mortality risk in individuals with type 2 diabetes.

An SD greater METs predicted lower cardiovascular disease mortality (HR, 0.45; RD, -1.65 cases/1000 person-years).

Increasing cardiorespiratory fitness can reduce the risk of cardiovascular disease mortality in individuals with type 2 diabetes.

Greater CRF is associated with reduced risks of mortality and cardiovascular disease events.

Enhancing cardiorespiratory fitness is crucial for lowering mortality and cardiovascular disease risks in this population.

Some patients with type 2 diabetes can experience sustained metabolic improvement to near-normal levels of glycemia, recognized as remission of diabetes.

Practitioners should recognize the potential for remission in T2DM patients.

The menstrual cycle-based training group (MC) showed a significant increase in fat free mass (FFM) of 1.7 ± 1.8 kg, but this was not statistically significant (P = 0.080).

Practitioners may consider menstrual cycle-based training for potential benefits in body composition.

Gynecologists play a pivotal role in the multidisciplinary approach to obesity management during menopause.

Gynecologists should integrate obesity management into routine care for menopausal women.

GLP-1 receptor agonists (GLP-1RAs) and combination therapy led to a significant decrease in mean glycated hemoglobin (HbA1c) levels by −3.5% at 12 months compared to DPP-4 inhibitors.

Practitioners can consider GLP-1RAs and combination therapy as effective options for managing HbA1c in liver transplant recipients with diabetes.

Alanine aminotransferase levels decreased with GLP-1RA and combination therapy.

Practitioners may consider monitoring liver enzyme levels when prescribing GLP-1RAs and combination therapy.

Dual-agonist and tri-agonist administration generally result in greater weight loss compared to GLP-1R agonists used alone.

Practitioners may consider dual- and tri-agonist therapies for enhanced weight loss in patients.

Combination therapies improve blood sugar and lipid levels compared to GLP-1R agonists alone.

Combination therapies may be beneficial for managing blood sugar and lipid levels in patients.

Emerging gut-peptide therapies further improve metabolic health outcomes for various metabolic diseases.

Practitioners should consider gut-peptide therapies for improving metabolic health in patients with metabolic diseases.

In males with type 2 diabetes, an intensive lifestyle intervention increased testosterone levels by 14% at year 1.

Practitioners should be aware of the increase in testosterone levels in males following weight loss interventions.

Changes in waist circumference due to the intensive lifestyle intervention were a significant mediator of sex hormone changes.

Practitioners should consider waist circumference changes when evaluating hormone level changes in patients.

Four nights of sleep restriction reduced low-dose insulin glucose infusion rate (GIR) by 20% and high-dose insulin GIR by 12% in postmenopausal women.

Practitioners should consider the impact of sleep restriction on insulin sensitivity in postmenopausal women.

Two days of recovery with optimal energy availability (OEA) partially restored performance but did not fully recover it to the level of the OEA group.

Recovery strategies should include optimal energy availability to aid performance recovery after low energy phases.

Resistance-trained individuals are capable of high absolute RIR accuracy when predicting 1 and 3 RIR on the barbell bench press exercise.

Practitioners can use RIR prescriptions to effectively gauge proximity to failure during resistance training.

High raw and absolute mean RIR accuracy for 1-RIR and 3-RIR predictions were observed.

The observed accuracy metrics can help inform training protocols.

Research over the last 3 decades has demonstrated the utility of GLP-1 receptor signaling for weight loss.

Long-term research supports the use of GLP-1 receptor signaling in weight loss strategies.

Tirzepatide is approved for the management of type 2 diabetes.

Healthcare providers can consider tirzepatide as a treatment option for patients with type 2 diabetes.

GLP-1 receptor agonists have shown early evidence of cardiovascular benefits in obese patients.

GLP-1 RAs may also be beneficial for cardiovascular health in obese patients.

Obesity increases stress throughout the musculoskeletal system and carries a higher risk for the development of osteoarthritis and various other musculoskeletal conditions.

Healthcare providers should consider the musculoskeletal risks associated with obesity when treating patients.

Obesity is associated with increased risk of complications in patients undergoing total joint arthroplasty.

Surgeons should be aware of the increased risks when treating obese patients in joint surgeries.